Addresses two key sources underlying type 2 inflammation in EoE1,2,a
NOT AN IMMUNOSUPPRESSANT1
aThe mechanism of dupilumab action has not been definitvely established.1
Studied across clinical, histologic, and endoscopic endpoints1,3,4
Demonstrated safety profile1
MOA, mechanism of action.
Support can make all the difference. DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.